2023 Connecticut General Statutes › Title 38a - Insurance › Chapter 700c - Health Insurance › Section 38a-492d. - Mandatory coverage for diabetes screening, testing and treatment.

(a) For the purposes of this section:
(1) “Diabetes device” has the same meaning as provided in section 20-616;
(2) “Diabetic ketoacidosis device” has the same meaning as provided in section 20-616;
(3) “Glucagon drug” has the same meaning as provided in section 20-616;
(4) “High deductible health plan” has the same meaning as that term is used in subsection (f) of section 38a-493;
(5) “Insulin drug” has the same meaning as provided in section 20-616;
(6) “Noninsulin drug” means a drug, including, but not limited to, a glucagon drug, glucose tablet or glucose gel, that does not contain insulin and is approved by the federal Food and Drug Administration to treat diabetes; and
(7) “Prescribing practitioner” has the same meaning as provided in section 20-571.
(b) Notwithstanding the provisions of section 38a-492a, each individual health insurance policy providing coverage of the type specified in subdivisions (1), (2), (4), (11) and (12) of section 38a-469 delivered, issued for delivery, renewed, amended or continued in this state shall provide coverage for the treatment of all types of diabetes. Such coverage shall include, but need not be limited to, coverage for medically necessary:
(1) Laboratory and diagnostic testing and screening, including, but not limited to, hemoglobin A1c testing and retinopathy screening, for all types of diabetes;
(2) Insulin drugs (A) prescribed by a prescribing practitioner, or (B) prescribed and dispensed pursuant to subsection (d) of section 20-616 once during a policy year;
(3) Noninsulin drugs (A) prescribed by a prescribing practitioner, or (B) prescribed and dispensed pursuant to subsection (d) of section 20-616 once during a policy year if the noninsulin drug is a glucagon drug;
(4) Diabetes devices in accordance with the insured's diabetes treatment plan, including, but not limited to, diabetes devices prescribed and dispensed pursuant to subsection (d) of section 20-616 once during a policy year; and
(5) Diabetic ketoacidosis devices in accordance with the insured's diabetes treatment plan, including, but not limited to, diabetic ketoacidosis devices prescribed and dispensed pursuant to subsection (d) of section 20-616 once during a policy year.
(c) Notwithstanding the provisions of section 38a-492a, no policy described in subsection (b) of this section shall impose coinsurance, copayments, deductibles and other out-of-pocket expenses on an insured that exceed:
(1) Twenty-five dollars for each thirty-day supply of a medically necessary covered insulin drug (A) prescribed to the insured by a prescribing practitioner, or (B) prescribed and dispensed pursuant to subsection (d) of section 20-616 once during a policy year;
(2) Twenty-five dollars for each thirty-day supply of a medically necessary covered noninsulin drug (A) prescribed to the insured by a prescribing practitioner, or (B) prescribed and dispensed pursuant to subsection (d) of section 20-616 once during a policy year if such noninsulin drug is a glucagon drug;
(3) One hundred dollars for a thirty-day supply of all medically necessary covered diabetes devices and diabetic ketoacidosis devices for such insured that are in accordance with such insured's diabetes treatment plan, including, but not limited to, diabetes devices and diabetic ketoacidosis devices prescribed and dispensed pursuant to subsection (d) of section 20-616 once during a policy year.
(d) The provisions of subsection (c) of this section shall apply to a high deductible health plan to the maximum extent permitted by federal law, except if such plan is used to establish a medical savings account or an Archer MSA pursuant to Section 220 of the Internal Revenue Code of 1986, or any subsequent corresponding internal revenue code of the United States, as amended from time to time, or a health savings account pursuant to Section 223 of said Internal Revenue Code, as amended from time to time, the provisions of said subsection (c) shall apply to such plan to the maximum extent that (1) is permitted by federal law, and (2) does not disqualify such account for the deduction allowed under said Section 220 or 223, as applicable.
(P.A. 97-268, S. 4; P.A. 17-15, S. 51; July Sp. Sess. P.A. 20-4, S. 13.)
History: P.A. 17-15 deleted references to October 1, 1997; July Sp. Sess. P.A. 20-4 added new Subsec. (a) re definitions, redesignated existing Subsec. (a) as Subsec. (b), amended same by adding reference to Sec. 38a-492a, adding “amended or continued”, adding coverage for treatment of all types of diabetes, designating provisions re laboratory and diagnostic screening coverage as Subdiv. (1), adding Subdiv. (2) re insulin drug coverage, adding Subdiv. (3) re noninsulin drug coverage, adding Subdiv. (4) re diabetes device coverage and adding Subdiv. (5) re diabetic ketoacidosis device coverage, deleted former Subsec. (b), added Subsec. (c) re limitations on coinsurance, copayments, deductibles and other out-of-pocket expenses, added Subsec. (d) re high deductible health plans, and made technical and conforming changes throughout, effective January 1, 2022.
See Sec. 38a-518d for similar provisions re group policies.